Transwin Group Presents Preliminary Data on Safety, Tolerability and Antitumor Activity of TST001 Monotherapy in China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress

SUZHOU, March 10, 2022 /PRNewswire/ -- Chuangsheng Group, a clinical-stage biopharmaceutical company with the ability to integrate the whole process of biopharmaceutical discovery, R&D, process development and production, announced that at the 2022 International Gastric Cancer Congress (IGCC) ) in the form of a poster to show the safety, tolerability and preliminary efficacy data of TST001 monotherapy in the Phase I clinical trial in China and its antitumor activity against gastric and pancreatic cancer

The primary objective of this Phase I study (NCT04495296) is to evaluate the safety and tolerability of TST001 in patients with advanced or metastatic solid tumors who have progressed during or after standard therapy and to determine the maximum tolerated dose ( MTD) and recommended dose for phase II study (RP2D)

During the dose escalation phase, patients who were not preselected for Claudin18.

In terms of efficacy, in the 6 mg/kg, Q3W dose-escalation cohort, 1 patient achieved a confirmed partial response at week 12 after receiving TST001, and the patient had received multiple lines of chemotherapy, anti-PD-1 and anti-VEGF therapy.

In Phase I clinical studies, TST001 demonstrated a manageable and tolerable safety profile in patients with advanced solid tumors, and in gastric and pancreatic cancer patients with Claudin18.

Dr.

Professor Shen Lin, Vice President of Peking University Cancer Hospital and Director of the Division of Digestive Oncology, said: "Gastric cancer is one of the most common malignant tumors in China.

About TST001

TST001 is a high-affinity humanized monoclonal antibody targeting Claudin18.

About Chuangsheng Group

Chuangsheng Group is a clinical-stage biopharmaceutical company with comprehensive capabilities in biopharmaceutical discovery, R&D, process development and production

Headquartered in Suzhou, Chuangsheng Group has successfully established a global business layout: there are drug discovery, clinical and translational research centers in Suzhou, and the headquarters of Chuangsheng Group and a production base with continuous perfusion production technology as its core technology are also under construction

Forward-Looking Statements

Information published in this press release may contain certain forward-looking statements

These forward-looking statements are based on the Company's management's current beliefs, assumptions, expectations, estimates, projections and understanding of future events at the time the statements are made

Source: Chuangsheng Group